Table of Contents
PISCATAWAY, N.J.– Camber Pharmaceuticals announced the addition of famotidine powder for oral suspension, USP to its current portfolio.
Famotidine powder for oral suspension, USP is indicated:
In adults for the treatment of:
- active duodenal ulcer (DU).
- active gastric ulcer (GU).
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy.
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of DU recurrence.
In pediatric patients 1 year of age and older for the treatment of:
- peptic ulcer disease.
- GERD with or without esophagitis and ulcerations.
In pediatric patients from birth to less than 1 year of age for the treatment of:
- GERD.
Famotidine 40 mg/5 mL powder for oral suspension, USP is available in a bottle to make 50 mL when reconstituted as directed.
